Bristol-Myers Squibb Company

BMY

US1101221083

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 12:40:19 2024-05-21 pm EDT			5-day change	1st Jan Change
42.58 ^USD	-1.79%		-4.82%	-17.06%

05:12pm	Bristol Myers: national schizophrenia campaign	CF
02:34pm	Bristol-Myers Squibb Says US FDA Reassigns Action Date Subcutaneous Nivolumab	MT

Tranche Update on Bristol-Myers Squibb Company's Equity Buyback Plan announced on October 27, 2016.

April 25, 2024 at 12:39 pm EDT

From January 1, 2024 to March 31, 2024, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 475,816,819 shares, representing 23.94% for $29,984.88 million under the buyback announced on October 27, 2016.

Latest news about Bristol-Myers Squibb Company

Bristol Myers: national schizophrenia campaign	11:12am	CF
Bristol-Myers Squibb Says US FDA Reassigns Action Date Subcutaneous Nivolumab	08:34am	MT
Bristol Myers: deadline set for subcutaneous Opdivo	07:32am	CF
Everlasting momentum	May. 16
Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma	May. 16	DJ
Bristol-Myers Squibb Gets FDA Accelerated Approval for Breyanzi for Follicular Lymphoma	May. 16	MT
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma	May. 15	CI
US FDA approves expanded use of Bristol's cancer cell therapy	May. 15	RE
Transcript : Bristol-Myers Squibb Company Presents at Bank of America Health Care Conference 2024, May-15-2024 11:20 AM	May. 15
Transcript : Bristol-Myers Squibb Company Presents at Guggenheim Securities Radiopharmaceuticals Day, May-13-2024 11:00 AM	May. 13
Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint	May. 10	MT
Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint	May. 10	DJ
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial	May. 10	CI
India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says	May. 10	RE
Declaration of Voting Results by Bristol-Myers Squibb Company	May. 09	CI
Declaration of Voting Results by Bristol-Myers Squibb Company	May. 09	CI
India's Alembic Pharma posts higher Q4 profit on strong N.America sales	May. 09	RE
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	May. 07	MT
Top Midday Stories: Tyson Shares Tumble on Earnings Miss; Robinhood Receives Wells Notice From SEC Staff; Spirit Airlines to Furlough up to 260 Pilots; Shell in Talks to Sell Malaysian Gas Station Business to Saudi Aramco	May. 06	MT
Bristol-Myers Squibb Says Applications for Opdivo Accepted by US, European Regulators	May. 06	MT
Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation	May. 06	DJ
Bristol-Myers: BLA accepted for subcutaneous Opdivo	May. 06	CF
U.S. Food and Drug Administration Accepts Bristol Myers Squibb?s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)	May. 06	CI
European Medicines Agency Validates Bristol Myers Squibb?s Application for Opdivo Plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite Instability?High or Mismatch Repair Deficient Metastatic Colorectal Cancer	May. 06	CI
HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50	May. 01	MT

Chart Bristol-Myers Squibb Company

Duration

Period

More charts

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

2024-07-26 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

43.36 USD

Average target price

53.19 USD

Spread / Average Target

+22.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-17.06%	87.9B
ELI LILLY AND COMPANY	+38.24%	705B
NOVO NORDISK A/S	+32.82%	583B
JOHNSON & JOHNSON	-3.64%	364B
MERCK & CO., INC.	+20.16%	332B
ABBVIE INC.	+5.12%	291B
ASTRAZENECA PLC	+16.64%	238B
ROCHE HOLDING AG	-4.13%	210B
NOVARTIS AG	+10.63%	209B
AMGEN INC.	+8.66%	169B

Other Pharmaceuticals

Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Tranche Update on Bristol-Myers Squibb Company's Equity Buyback Plan announced on October 27, 2016.

EPS Revisions